Trial Profile
A Phase 2 Study of PCM-075 (Onvansertib) in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Onvansertib (Primary) ; Abiraterone acetate; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms UNITE
- Sponsors Cardiff Oncology
- 31 Oct 2023 Status changed from active, no longer recruiting to completed.
- 25 Aug 2023 Planned End Date changed from 1 Jul 2023 to 1 Sep 2023.
- 25 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Sep 2023.